Horizon Therapeutics’ $65 Million Acquisition of Manufacturing Facility from EirGen

Matheson advised Horizon Therapeutics on its acquisition of EirGen Pharma’s manufacturing facility in County Waterford.

Horizon Therapeutics (NASDAQ: HZNP) will acquire the 44,000 square foot EirGen manufacturing facility, valued at over $65 million. 

The transaction, which is subject to customary closing conditions, is expected to close in the third quarter of 2021 and will be a significant boost to the Life Science ecosystem in the South East.

The transaction will also see a number of EirGen’s employees transfer to Horizon, and the creation of a further 50 new roles over the next 18 months. 

Horizon Therapeutics is focused on medicines that address critical needs for peoples suffering from rare and rheumatic diseases.

The Matheson team consisted of Corporate M&A partner David Fitzgibbon (Picture), Commercial Real Estate partner Sally Anne Stone and Corporate M&A associate, John Coary. 

Involved fees earner: John Coary – Matheson; David Fitzgibbon – Matheson; Sally Anne Stone – Matheson;

Law Firms: Matheson;

Clients: Horizon Therapeutics;

Author: Federica Tiefenthaler